Z. Abbasi Radmoghaddama,b, M. Dastjerdib, N. Garaeib, E. Mohammadib, S. Akbarib, G. Torkamandsarabib, A. Akbaria*
aGreenNanoTech Kft, Király Utca 80, Budapest, 1068, Hungary
bNanoSciTec GmbH, Hermann Weinhauser str. 67, Munich, 81867, Germany
Despite the remarkable medical advances, cancer is still a lethal threat to humans, causing tremendous social and economic problems. The emerging and following developments of nanomedicine for cancer therapy during past recent years brought outstanding achievements to the healthcare industry. Nanoparticle-based carriers to deliver various anti-cancer drugs opened new doors to boost the efficiencies of conventional chemotherapeutic approaches and decrease serious side effects. Although some challenges like drug resistance, instability, inappropriate accumulation, and drug leakage have remained, some delivery systems have achieved hopeful results in clinical trials, and consequently, some of them were approved by U.S Food and Drug Administration (FDA). In this review, the most essential and promising anticancer drug delivery systems for cancer treatment, particularly non-small cell lung cancer (NSCLC), are described. The primary emphasis was on evaluating different FDA-Approved ones in order to get a comprehensive grasp of their benefits and drawbacks for future research and industrial uses.
Keywords: Cancer therapy, Drug delivery systems, NSCLC, Lipid nanocarriers, Nanomedicine, Targeted delivery
© Article info: Accepted by: 12 August 2022, Published by: 24 August 2022.